Recipients with AML Transformed from MDS

Historically, for recipients transplanted for AML transformed from MDS, the pre-HCT disease status should have been reported as either Primary Induction Failure (PIF) or relapse if there was continued evidence of MDS at the time of assessment, even if the AML was in Complete Remission (CR).

Effective immediately, for all recipients transplanted for AML transformed from MDS, if all criteria are met for AML CR at the time of transplant but there is continued evidence of MDS, the disease status should now be reported as Complete Remission. These criteria include <5% blasts in the bone marrow as well as 0% blasts in the peripheral blood.

The same criteria apply post-HCT as well. In other words, if there was continued evidence of MDS on a post-HCT bone marrow without evidence of AML, the disease status should be reported as CR.

This instruction only applies to forms completed in May 2020 and forward. Disease statuses previously submitted following the prior instruction should not be updated unless instructed to do so by the CIBMTR.

Questions, feedback, or requests may be submitted through the CIBMTR Customer Service Center or an email may be submitted to CIBMTRFormsManualComments@nmdp.org.